MedPath

Temsirolimus

Generic Name
Temsirolimus
Brand Names
Torisel
Drug Type
Small Molecule
Chemical Formula
C56H87NO16
CAS Number
162635-04-3
Unique Ingredient Identifier
624KN6GM2T
Background

Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.

Indication

For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.

Associated Conditions
Advanced Renal Cell Carcinoma
Clinical Trials
Related News

Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

Phase 2
Active, not recruiting
Conditions
Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Desmoplastic Small Round Cell Tumor
Ewing Sarcoma of Bone or Soft Tissue
Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Interventions
Procedure: surgery
Radiation: radiation
First Posted Date
2013-09-19
Last Posted Date
2025-03-26
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
24
Registration Number
NCT01946529
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1
Completed
Conditions
Recurrent Adult Hodgkin Lymphoma
Interventions
Other: Laboratory Biomarker Analysis
First Posted Date
2013-07-18
Last Posted Date
2015-11-09
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
3
Registration Number
NCT01902160
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Phase 2
Withdrawn
Conditions
Stage IV Melanoma
Recurrent Melanoma
Stage III Melanoma
Melanoma
Interventions
First Posted Date
2013-05-10
Last Posted Date
2015-04-15
Lead Sponsor
National Cancer Institute (NCI)
Registration Number
NCT01851408

Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer

Phase 2
Completed
Conditions
Relapsed Bladder Cancer
Interventions
First Posted Date
2013-04-10
Last Posted Date
2021-05-06
Lead Sponsor
Institut Bergonié
Target Recruit Count
54
Registration Number
NCT01827943
Locations
🇫🇷

CHU de Bordeaux, Bordeaux, France

🇫🇷

Centre François Baclesse, Caen, France

🇫🇷

Centre Léon Bérard, Lyon, France

and more 6 locations

Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer

Phase 2
Completed
Conditions
HER2-mutant Non-Small Cell Lung Cancer
Interventions
First Posted Date
2013-04-09
Last Posted Date
2018-07-03
Lead Sponsor
Puma Biotechnology, Inc.
Target Recruit Count
62
Registration Number
NCT01827267
Locations
🇺🇸

Johns Hopkins, Baltimore, Maryland, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 18 locations

A Post Marketing Surveillance As Required By Philippine Food And Drug Administration

Withdrawn
Conditions
Renal Cell Carcinoma
Interventions
First Posted Date
2013-02-01
Last Posted Date
2013-05-01
Lead Sponsor
Pfizer
Registration Number
NCT01781442

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

Phase 2
Completed
Conditions
Ganglioneuroblastoma
Recurrent Neuroblastoma
Interventions
Biological: Dinutuximab
Other: Laboratory Biomarker Analysis
Biological: Sargramostim
First Posted Date
2013-01-14
Last Posted Date
2022-10-24
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
73
Registration Number
NCT01767194
Locations
🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

Nationwide Children's Hospital, Columbus, Ohio, United States

🇺🇸

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 154 locations

Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males

First Posted Date
2012-10-24
Last Posted Date
2019-11-08
Lead Sponsor
Celgene
Target Recruit Count
31
Registration Number
NCT01712828
Locations
🇺🇸

Covance Clinical Research Unit Dallas, Dallas, Texas, United States

Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma

Phase 2
Completed
Conditions
Hepatocellular Carcinoma
Interventions
First Posted Date
2012-09-19
Last Posted Date
2020-12-07
Lead Sponsor
University of California, San Francisco
Target Recruit Count
29
Registration Number
NCT01687673
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

🇺🇸

Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois, United States

Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

Phase 3
Completed
Conditions
Mantle Cell Lymphoma
Interventions
First Posted Date
2012-07-20
Last Posted Date
2018-01-19
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
280
Registration Number
NCT01646021
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy